Genmab AS Valuation
| GNMSF Stock | USD 212.50 4.81 2.32% |
At this time, the firm appears to be overvalued. Genmab AS retains a regular Real Value of $189.79 per share. The prevalent price of the firm is $212.5. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Current Valuation of 26.41 B, return on equity of 0.24, and Return On Asset of 0.1 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Genmab AS's price fluctuation is very steady at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Genmab pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Genmab AS. Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Pink Sheet. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 212.5 | Real 189.79 | Hype 212.5 | Naive 212.3 |
The real value of Genmab Pink Sheet, also known as its intrinsic value, is the underlying worth of Genmab AS Company, which is reflected in its stock price. It is based on Genmab AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Total Value Analysis
Genmab AS is currently projected to have takeover price of 26.41 B with market capitalization of 26.78 B, debt of 634 M, and cash on hands of 21.61 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genmab AS fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.41 B | 26.78 B | 634 M | 21.61 B |
Genmab AS Investor Information
About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.2. Genmab AS recorded earning per share (EPS) of 12.0. The entity had not issued any dividends in recent years. Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Genmab AS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genmab AS has an asset utilization ratio of 34.44 percent. This implies that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Genmab AS is more efficient with each dollar of assets it utilizes for everyday operations.Genmab AS Ownership Allocation
Genmab AS has a total of 65.96 Million outstanding shares. 30% of Genmab AS outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genmab AS Profitability Analysis
The company reported the revenue of 8.48 B. Net Income was 3.01 B with profit before overhead, payroll, taxes, and interest of 8.48 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Genmab AS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Genmab AS and how it compares across the competition.
About Genmab AS Valuation
The pink sheet valuation mechanism determines Genmab AS's current worth on a weekly basis. Our valuation model uses a comparative analysis of Genmab AS. We calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab AS's related companies.Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.
8 Steps to conduct Genmab AS's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Genmab AS's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Genmab AS's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Genmab AS's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Genmab AS's revenue streams: Identify Genmab AS's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Genmab AS's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Genmab AS's growth potential: Evaluate Genmab AS's management, business model, and growth potential.
- Determine Genmab AS's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Genmab AS's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Genmab AS Growth Indicators
Investing in growth stocks can be very risky. If the company such as Genmab AS does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 65.7 M | |
| Quarterly Earnings Growth Y O Y | 1.908 | |
| Forward Price Earnings | 35.0877 | |
| Retained Earnings | 10 B |
Complementary Tools for Genmab Pink Sheet analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |